Pink Sheet reporter and editors discuss Moderna CEO’s Stéphane Bancel’s defense of his company and COVID-19 vaccine pricing at the Senate Health, Education, Labor and Pensions Committee, the NIH denying a petition to use government march-in rights for Xtandi, and Tofersen receiving a positive US FDA advisory committee recommendation for use in ALS.

More on these topics from The Pink Sheet:

Moderna CEO Hearing Highlights Dissatisfaction With Patient Assistance Programs

https://pink.pharmaintelligence.informa.com/PS147930/Moderna-CEO-Hearing-Highlights-Dissatisfaction-With-Patient-Assistance-Programs

Moderna CEO Reminds People About Value Of Government Negotiations At Senate Hearing

https://pink.pharmaintelligence.informa.com/PS147939/Moderna-CEO-Reminds-People-About-Value-Of-Government-Negotiations-At-Senate-Hearing

After Xtandi, Will Government Ever Seek March-In Rights Over Drug Pricing?

https://pink.pharmaintelligence.informa.com/PS147929/After-Xtandi-Will-Government-Ever-Seek-MarchIn-Rights-Over-Drug-Pricing

Xtandi Still Faces Likely US Price Cut Even As It Avoids ‘March In’ Proceeding

https://pink.pharmaintelligence.informa.com/PS147940/Xtandi-Still-Faces-Likely-US-Price-Cut-Even-As-It-Avoids-March-In-Proceeding

Accelerated Approval Is US FDA Panel’s Preferred Path For Biogen/Ionis’s Tofersen In ALS

https://pink.pharmaintelligence.informa.com/PS147918/Accelerated-Approval-Is-US-FDA-Panels-Preferred-Path-For-BiogenIoniss-Tofersen-In-ALS

Accelerated Approval: Potential Sources Of Confirmatory Evidence Weighed At Tofersen Review

https://pink.pharmaintelligence.informa.com/PS147937/Accelerated-Approval-Potential-Sources-Of-Confirmatory-Evidence-Weighed-At-Tofersen-Review